2016 - Page 2 of 3 - MS-Docblog

Grafische Darstellung einer Liquorentnahme.

The Lumbar Puncture – When and Why is it Necessary?

10. August 2016 Prof. Dr. med. Mathias Mäurer Diagnosis MS

An unpopular but necessary procedure in the diagnosis of Multiple Sclerosis is the removal of cerebrospinal fluid, the lumbar puncture. The diagnosis of MS is made today using the so-called McDonald criteria. These criteria are

The EDSS Scale

21. July 2016 Prof. Dr. med. Mathias Mäurer General

For the neurologist who deals with MS, the EDSS scale is as commonplace as the trowel for the mason. However, this carries the risk that as a neurologist, one assumes that the EDSS scale is

Traveling with MS

24. June 2016 Prof. Dr. med. Mathias Mäurer Life with MS

The topic of travel must be considered individually, people who already have restrictions due to the disease will choose their destination and accommodation with a view to their individual restrictions and will also have very

Natalizumab – what does the JCV antibody index mean?

9. June 2016 Prof. Dr. med. Mathias Mäurer General

Lately, I’ve been receiving more inquiries from Tysabri patients (active ingredient Natalizumab), who are worried about a high JCV antibody index that has been measured in them. Therefore, I would like to briefly explain what

Lymphocytopenia under Tecfidera

27. May 2016 Prof. Dr. med. Mathias Mäurer MS Therapy

Dimethyl fumarate (Tecfidera®) has established itself as a first-line therapy for the treatment of multiple sclerosis. The availability of an effective oral therapy with a favorable side effect profile has expanded the possibilities of MS

Impressions from the AAN Congress (3) – Clinical Studies

22. April 2016 Prof. Dr. med. Mathias Mäurer General

Presentations of clinical trials for new MS drugs take up a large space at the AAN. It must be said somewhat restrictively that real news is rare at this point. Essentially, evaluations of subgroup analyses

Impressions from the AAN Congress (2) – Biomarker

21. April 2016 Prof. Dr. med. Mathias Mäurer General

With the large selection of drugs for MS therapy, the question often arises as to which drug is the right one for the individual patient. We lack reliable biomarkers for an assignment. The term biomarker

Impressions from the AAN Congress – Risk Factors (1)

20. April 2016 Prof. Dr. med. Mathias Mäurer General

This week, the annual meeting of the American Academy of Neurology (AAN) is taking place in Vancouver. For neurologists, this conference is one of the most important events of the year, as clinicians and scientists

Fatigue and MS

15. April 2016 Prof. Dr. med. Mathias Mäurer MS Symptoms

People with MS often suffer from a sometimes very debilitating physical and mental fatigue, which is referred to in clinical practice as “fatigue”. Despite its importance for many MS patients, “fatigue” is not well defined,

MS and Age

4. April 2016 Prof. Dr. med. Mathias Mäurer General

“Time plays for you” – this is a common statement when therapy decisions are pending for older MS patients. I probably have to define what older MS patients are first. Immunologically speaking, these are MS

Year: 2016

The Lumbar Puncture – When and Why is it Necessary?

The EDSS Scale

Traveling with MS

Natalizumab – what does the JCV antibody index mean?

Lymphocytopenia under Tecfidera

Impressions from the AAN Congress (3) – Clinical Studies

Impressions from the AAN Congress (2) – Biomarker

Impressions from the AAN Congress – Risk Factors (1)

Fatigue and MS

MS and Age

Thank You!

Recent Posts

Archive

Categories

Links

Follow us

The Expert

The Topics

The Community